Meeting
2021 ASCO Annual Meeting
Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.
Authors
Yasmeen Rauf
Cleveland Clinic, Cleveland, OH
Yasmeen Rauf , Rachel Hufsey , Kathy Robinson , John H. Suh , Samuel T. Chao , Erin Sennett Murphy , Jennifer S. Yu , David M. Peereboom , Manmeet Singh Ahluwalia , Wei Wei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03514069
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2060)
DOI
10.1200/JCO.2021.39.15_suppl.2060
Abstract #
2060
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report.
First Author: Manmeet Singh Ahluwalia
Poster
2022 ASCO Annual Meeting
Phase 1 trial of ruxolitinib, temozolomide, and radiation in high-grade gliomas.
First Author: Manmeet Singh Ahluwalia
Poster
2023 ASCO Annual Meeting
Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy for newly diagnosed glioblastoma.
First Author: Samuel Ryu
Poster
2023 ASCO Annual Meeting
Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601).
First Author: Matthias Holdhoff